BMS pays Tranzyme $10 million up front to MATCH up
This article was originally published in Scrip
Executive Summary
Tranzyme Pharma has entered into a strategic collaboration agreement with Bristol-Myers Squibb (BMS) to discover, develop and commercialise macrocyclic compounds directed against targets of interest to BMS in multiple indications.